Clinical trial NCT02966171: A Dose Escalation Study to Assess the Safety and Tolerability of HMPL-453 in Patients With Advanced Solid Malignancies
Official title: A Phase I, Open-label, Multi-center, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of HMPL-453 in Patients With Advanced Solid Malignancies
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Solid Tumor
Keywords: Advanced Solid Malignancies
Lead sponsor: Hutchmed
Sponsor class: INDUSTRY
First posted: 2016-11-17
Enrollment: 14
Sex: ALL
Minimum age (years): 25
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a first-time-in-human, phase I, open-label, dose-escalation study of HMPL-453 in patients with advanced or metastatic solid malignancies who have failed or are intolerable to standard therapies or for whom no standard therapies exist. There are preliminary two stages in this study: a dose-escalation stage (stage 1) and a dose-expansion stage (stage 2). We will decide whether to conduct stage 2 or not one month after the last patient included in stage 1.

Detailed description: Dose-escalation stage (stage 1): Patients participating in the dose-escalation stage will take a single dose of HMPL-453 on Day 1 and will be followed for one week for safety observations. After one week of observation, if no safety issues occur, patients can continue multiple dosing of HMPL-453 QD and start on the DLT assessment cycles. Each cycle consists of 28-days. Patients are required to draw blood samples for PK and safety analysis at specific time points during the treatment.

The 3+3 design will be employed for the dose escalation and MTD determination. To limit the number of patients being exposed to potentially ineffective doses, one patient will be enrolled and dosed in the initial dose cohort. If there are no DLT or \< 2 CTCAE grade 2 toxicities occur in the first treatment cycle, then the study will be escalated to the next dose cohort. Otherwise, the trial will revert to a standard 3+3 design.

Dose-Expansion Stage (Stage 2): This stage is to further evaluate the safety, tolerability, PD profile, and preliminary anti-tumor activity of HMPL-453 at the RP2D in approximately 10 patients with advanced solid tumor. Patients with FGFR dysregulated advanced solid tumors, including but not limited to, advanced gastric cancer, advanced urothelial bladder cancer, or advanced cholangiocarcinoma (patients with cancers of the gallbladder or ampulla of Vater are not eligible) are preferred to be enrolled.

Expansion stage will begin after dose-escalation stage is completed and the MTD/RP2D has been determined. Patients will receive HMPL-453 with 28-day treatment cycles until disease progression, death, intolerable toxicity, no longer benefiting from the study treatment per investigator's discretion, or withdrawal of consent, whichever comes first.

Eligibility criteria: Inclusion Criteria:

* In the dose escalation stage, patients with locally advanced, or metastatic solid tumor who have failed, or intolerable to, standard therapies or for whom no standard therapies exist will be enrolled.
* In the dose expansion stage, patients with locally advanced, or metastatic solid tumor and FGFR dysregulation who have failed or intolerable to standard therapies or no standard therapies exist are to be enrolled.
* In the dose escalation stage: evaluable or measurable disease according to RECIST Version 1.1. In the dose expansion stage: measurable disease according to RECIST Version 1.1.
* Life expectancy of at least 12 weeks.
* ECOG performance status of 0 or 1

Exclusion Criteria:

* Prior or current treatment with any selective FGFR inhibitor.

Primary outcomes:
measure: Incidence of DLTs by the NCI CTCAE v4.03
timeFrame: Cycle 1 (DLT assessment window, 28 days) of multiple dosing peroid
Secondary outcomes:
measure: Incidence of AEs, clinically significant laboratory abnormalities, and electrocardiographic (ECG) changes and vital signs
timeFrame: from first dose to 30 days after last dose of study treatment
measure: maximum plasma concentration (Cmax)
timeFrame: from first dose to day 56 of multiple dosing peroid
measure: time to reach maximum concentration (Tmax)
timeFrame: from first dose to day 56 of multiple dosing peroid
measure: terminal half-life (t1/2)
timeFrame: from first dose to day 56 of multiple dosing peroid
measure: area under the concentration-time curve (AUC0-t)
timeFrame: from first dose to day 56 of multiple dosing peroid
measure: apparent clearance (CL/F)
timeFrame: from first dose to day 56 of multiple dosing peroid
measure: Serum phosphate level increases
timeFrame: from first dose to Day 21 of the last treatment cycle
measure: Objective response rate (ORR)
timeFrame: Every 8 weeks while being treated with HMPL-453 (expected average of 16 weeks)
measure: Duration of response (DoR)
timeFrame: Every 8 weeks while being treated with HMPL-453 (expected average of 16 weeks)
measure: Disease Control Rate (DCR)
timeFrame: Every 8 weeks while being treated with HMPL-453 (expected average of 16 weeks)
measure: Change in tumor size
timeFrame: Every 8 weeks while being treated with HMPL-453 (expected average of 16 weeks)
measure: Progression free survival (PFS)
timeFrame: Every 8 weeks while being treated with HMPL-453 (expected average of 16 weeks)
Other outcomes:
measure: FGFR genetic alterations status
timeFrame: expected average of 16 weeks
measure: FGFR pathway inhibition by pERK
timeFrame: from first dose to Day 15 of the first treatment cycle
Locations:
city: Sydney
country: Australia
facility: St Vincent's Cancer Services
state: New South Wales
city: Sydney
country: Australia
facility: Chris O'Brien Lifehouse
state: New South Wales
city: Frankston
country: Australia
facility: Peninsula and Southeast Oncology
state: Victoria
city: Melbourne
country: Australia
facility: Monash Medical Centre
state: Victoria
Study officials:
affiliation: Hutchison Medipharma Limited
name: Weiss Yang
role: STUDY_DIRECTOR
References: